Yuhan (A000100) Stock Overview
Manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
A000100 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Yuhan Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩104,600.00 |
| 52 Week High | ₩166,900.00 |
| 52 Week Low | ₩74,700.00 |
| Beta | 0.70 |
| 1 Month Change | -1.51% |
| 3 Month Change | -18.15% |
| 1 Year Change | 38.36% |
| 3 Year Change | 108.16% |
| 5 Year Change | 139.89% |
| Change since IPO | 8,963.15% |
Recent News & Updates
Yuhan Corporation's (KRX:000100) Intrinsic Value Is Potentially 32% Above Its Share Price
May 22
There May Be Some Bright Spots In Yuhan's (KRX:000100) Earnings
Mar 19Is Yuhan (KRX:000100) Using Too Much Debt?
Mar 11Recent updates
Yuhan Corporation's (KRX:000100) Intrinsic Value Is Potentially 32% Above Its Share Price
May 22There May Be Some Bright Spots In Yuhan's (KRX:000100) Earnings
Mar 19Is Yuhan (KRX:000100) Using Too Much Debt?
Mar 11Investor Optimism Abounds Yuhan Corporation (KRX:000100) But Growth Is Lacking
Feb 21Calculating The Intrinsic Value Of Yuhan Corporation (KRX:000100)
Dec 21Yuhan Corporation (KRX:000100) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Nov 14Is Yuhan (KRX:000100) Using Too Much Debt?
Oct 08Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)
Sep 16Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%
Aug 28Yuhan Corporation's (KRX:000100) Price In Tune With Earnings
Jul 01Shareholder Returns
| A000100 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.5% | -0.9% | 2.9% |
| 1Y | 38.4% | 4.9% | 3.6% |
Return vs Industry: A000100 exceeded the KR Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: A000100 exceeded the KR Market which returned 3.6% over the past year.
Price Volatility
| A000100 volatility | |
|---|---|
| A000100 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in KR Market | 12.4% |
| 10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A000100 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A000100's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 2,038 | Wook-Je Cho | www.yuhan.co.kr |
Yuhan Corporation manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally. It also manufactures and sells animal feed and health functional food. The company was founded in 1926 and is headquartered in Seoul, South Korea.
Yuhan Corporation Fundamentals Summary
| A000100 fundamental statistics | |
|---|---|
| Market cap | ₩7.90t |
| Earnings (TTM) | ₩65.71b |
| Revenue (TTM) | ₩2.11t |
Is A000100 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000100 income statement (TTM) | |
|---|---|
| Revenue | ₩2.11t |
| Cost of Revenue | ₩1.41t |
| Gross Profit | ₩702.18b |
| Other Expenses | ₩636.47b |
| Earnings | ₩65.71b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 882.52 |
| Gross Margin | 33.20% |
| Net Profit Margin | 3.11% |
| Debt/Equity Ratio | 17.2% |
How did A000100 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/17 07:35 |
| End of Day Share Price | 2025/06/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Yuhan Corporation is covered by 34 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Young-Ah Han | BofA Global Research |
| Hyeryeong Kim | CGS International |
| Hyonseok Kim | CLSA |